Background In a previous systematic review and meta-analysis, we assessed the efficacy
and safety of nonvitamin-K antagonist oral anticoagulants versus warfarin in patients with …

Background and Purpose—To assess whether the combined analysis of all phase III trials of
nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Non-vitamin K antagonist oral anticoagulants (NOACs) are frequently used to prevent stroke
in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet …

Background: Warfarin reduces ischemic stroke in atrial fibrillation, but has numerous
limitations. Novel oral anticoagulants provide more predictable anticoagulation with fewer …

Introduction and objectives To assess the effectiveness of direct oral anticoagulants vs
vitamin K antagonists in real-life patients with atrial fibrillation. Methods A systematic review …

Background: Vit-K antagonists are the therapy of choice to prevent thromboembolic events
due to atrial fibrillation since many years. New oral anticoagulants (NOA) showed …

The aims of this article are to review the evidence regarding the use of non-vitamin K oral
anticoagulants (NOACs) for secondary stroke prevention as compared to vitamin K …